Arrow-right Camera

The Spokesman-Review Newspaper The Spokesman-Review

Saturday, October 24, 2020  Spokane, Washington  Est. May 19, 1883
Clear Day 35° Clear

Tag search results

Tags let us describe our content with keywords, making it easier to find what you're most interested in. Use the search box to look for tags, or explore our coverage with the lists below.


Group with consumer-friendly vibe pushes drugmakers’ message

As Congress and President Donald Trump’s administration aim to lower prescription drug costs, outside groups like the Alliance for Patient Access are seeking to sway the outcome. But not all of these organizations are clear about who they actually represent. Their names can obscure the source of the message, and they’re cagey about where they get their funding.

Liberals dare Trump to back their bills lowering drug prices

Challenging President Donald Trump to make good on his pledge to cut prescription drug prices, congressional liberals proposed legislation Thursday to bring U.S. prices in line with the much lower costs in other countries.

Froma Harrop: Forget about cheaper drugs on Trump’s watch

President Trump’s plan for lowering Medicare drug costs is good, even cutting-edge. As Democrats successfully campaign on health care, Trump has come back with a proposal that could save Medicare patients and taxpayers $17.2 billion over five years. Too bad its chances of happening are close to nil. We’ve seen this talkie before. As Election Day approaches, Trump makes a promise that seems to favor the public over big-money interests. The moment the last vote is counted, it vanishes.

Trump’s prescription to reduce drug prices takes small steps

President Donald Trump’s long-awaited plan to bring down drug prices, unveiled Friday, will mostly spare the pharmaceutical industry he previously accused of “getting away with murder” and instead focus on increasing private competition and requiring more openness about costs.

Generic-drugs firms under U.S. probe

U.S. prosecutors are examining the prices of skin treatments made by Perrigo Co. and a handful of other companies as part of a sweeping criminal investigation into possible collusion in the generic drug business, according to a document filed in court this week.

Trump calls drug pricing ‘astronomical’ and promises changes

President Donald Trump told drugmakers at a White House meeting Tuesday they were charging too much and promised to get better bargains for government health programs, in addition to finding ways to get new medicines to market faster.

Albert R. Hunt: Trump could make headway on drug prices

There are arguments over the merits and effects, but the politics are clear cut. In a Kaiser Foundation poll last autumn, the public, by 82 percent to 17 percent, favored allowing the federal government to negotiate lower drug prices.

Secret rebates erode drugmaker revenue, industry study says

Branded drug companies’ share of total U.S. spending on their products is declining, in part because of an increase in secret rebates paid to middlemen, according to an analysis sponsored by an industry group that’s been seeking to deflect scrutiny of rising prices.

Consumer Confidential: Insulin price hikes aren’t sweet

A key feature of Republican plans to replace Obamacare is allowing market forces to boost innovation and competition among health care providers. “Unleashing the power of choice and competition is the best way to lower health care costs and improve quality,” declares House Speaker Paul Ryan in his conservative manifesto “A Better Way.”

Shkreli says ‘of course’ he’d raise drug price again

Outspoken former pharmaceutical executive Martin Shkreli said the national outrage over drug pricing was blown out of proportion and heightened by the U.S. presidential election, although he conceded he could have predicted the criticism better.

Pharmaceutical industry gearing up to defend drug prices

The skyrocketing costs of prescription drugs has been noticeably absent from discussion in the presidential debates – even as bipartisan anger about price gouging has united Congress. But the trade group for the pharmaceutical industry, PhRMA, is gearing up to defend drug prices after the election, seeking an additional $100 million in annual dues from its members, according to a report from Politico.